COVID-19 Treatment AND Vaccine Tracker
Last Updated:
July 9, 2020 10:17 PM
Pacific
FasterCures, a center of the Milken Institute, is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). This tracker contains an aggregation of publicly-available information from validated sources.
Explore detailed information on each development:
Download a .CSV and explore relationships:
Spreadsheet
Understand definitions of the terms and how our researchers distinguish stages of development:
Glossary
See the race for a
vaccine visualized
Drug developers, academic labs, and other organizations globally are developing many different kinds of medical products to treat COVID-19. Treatments give us tools to help patients while a vaccine is developed. Potential treatments include medicines currently used or studied to treat other diseases (“repurposed” treatments), as well as drugs newly identified or designed to treat COVID-19.
Alexion Pharmaceuticals
Ultomiris (ravulizumab-cwvz), complement inhibitor
clinical
Phase III to start in May 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04369469
Assistance Publique - Hopitaux de Paris (Phase II); Alexion (Expanded Access Protocols)
Soliris (eculizumab), complement inhibitor
clinical
Phase II recruiting May 2020. Expanded access protocols
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04288713 NCT04346797 NCT04355494
AstraZeneca; ACCORD trial
MEDI3506, monoclonal antibody targeting interleukin 33
clinical
ACCORD Phase II trial to start May 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Chronic Obstructive Pulmonary Diesase
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Celltrion
Remsima (infliximab), anti-TNF antibody
clinical
Phase II trial to start in June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Cerecor
CERC-002, anti-LIGHT monoclonal antibody
clinical
Phase 2 to start in June 2020, top line data expected 4Q 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Pediatric Crohn's Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
CytoDyn
leronlimab (PRO 140), a CCR5 antagonist
clinical
Phase II trial (mild/moderate) met enrollment in June 2020; Phase IIb/III trial (severe) ongoing June 2020, interim results expected June/July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04343651 NCT04347239
EUSA Pharma / The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica
Sylvant (siltuximab), interleukin-6 targeted monoclonal
clinical
FDA approves Phase III trial in hospitalized patients in July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04322188 NCT04330638 NCT04329650
Eli Lilly
LY3127804, anti-Angiopoietin 2 (Ang2) antibody
clinical
Phase II to start in April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Eli Lilly / AbCellera (NIH Vaccines Research Center)
LY-CoV555 antibody from recovered patients
clinical
Phase 1 started June 2020; results expected end of June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
GSK
otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody
clinical
Phase II recruiting June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
To treat rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04376684
Humanigen Inc.
lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody
clinical
Data on first clinical use released June 2020; Phase III trial recruiting June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04351152
I-Mab Biopharma
TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody
clinical
Interim Phase I/II data released June 2020, part 2 of the study to start June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04341116
Implicit Bioscience
IC14, recombinant chimeric anti-CD14 monoclonal antibody
clinical
Expanded access protocols
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Acute Respiratory Distress Syndrome
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04346277
InflaRx N.V.
IFX-1, anti-C5a antibody
clinical
Phase II topline results reported June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04333420
Junshi Biosciences / Eli Lilly
JS016 antibody candidate
clinical
Phase I trial in China started June 2020; trial in US to start 2H 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Kiniksa/ Cleveland Clinic/ Ospedale San Raffaele
mavrilimumab, anti-granulocyte-macrophase colony-stimunlating factor receptor-alpha monoclonal antibody
clinical
Phase II trial recruiting June 2020; Case reports published June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Giant cell arteritis (GCA); rheumatoid arthritis; large B-cell lymphoma (with Yescarta)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04399980, NCT04397497
Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes; RECOVERY trial
Convalescent plasma (blood plasma from recovered patients)
clinical
Mayo Clinic and Houston Methodist trial results published June 2020, other trials ongoing
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clinicaltrials.gov, including: NCT04321421, NCT04292340, NCT04316728, NCT04338360, NCT04345289, NCT04349410, NCT04346589, NCT04333251, NCT04361253, NCT04323800, NCT04359810, NCT04362176, NCT04354831, NCT04360486, NCT04321421, NCT04441424
Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital
Octagam; intravenous Immunoglobulin (IVIG)
clinical
Sharpy Memorial Hospital preliminary data released June 2020; Phase III trial to start May 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04261426 NCT04264858 NCT04350580
Novartis; other research sponsors
Ilaris (canakinumab), interleukin-1beta blocker
clinical
Novartis Phase III to start and trial top-line results expected late summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04348448 NCT04362813 NCT04365153
Numerous trials with Chinese research sponsors
PD-1 blocking antibody; Thymosin
clinical
Phase II study not yet recruiting
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04268537 ChiCTR2000030028
Numerous trials with Chinese research sponsors; Roche
Avastin (bevacizumab), vascular endothelial growth factor inhibitor
clinical
Phase II/III studies recruiting April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04275414 NCT04305106 NCT04344782
Numerous trials with global research sponsors; Roche; REMAP-CAP; RECOVERY
Actemra (tocilizumab), interleukin-6 receptor antagonist
clinical
Initial Roche studies could be completed May or June 2020; Phase II open label study in Italy active (April 2020), Phase III Roche global trial enrolling May 2020, Roche trial (+ remdesivir) to start June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04317092, NCT04320615, NCT04310228, ChiCTR2000030894, NCT04306705, ChiCTR2000030442, ChiCTR2000029765, NCT04322773, NCT04345445, NCT04331795, NCT04332094, NCT04346355, NCT04359667, NCT04332913, NCT04335071, NCT04356937, NCT04361032, NCT04315480, NCT04339712, NCT04333914, NCT04361552, NCT04330638, NCT04331808, NCT02735707, NCT04349410, NCT04363736, NCT04372186, NCT04363853
Regeneron/ NIAID
Antibody combination REGN-COV2 (REGN10933+REGN10987) against the spike protein
clinical
Joined Operation Warp Speed in July 2020; Phase III prevention trial with NIAID starts July 2020; Phase II stage of I/II/III treatment trial started July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04425629, NCT04426695
Roivant Sciences
Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal
clinical
Phase II study started in April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04351243
Sanofi / Regeneron; Feinstein Institutes; REMAP-CAP global trial
Kevzara (sarilumab), interleukin-6 receptor antagonist
clinical
Phase III (US) results released July 2020 and US trial stopped, Phase III (ex-US in severe and critical hospitalized patients continues) results expected 3Q 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04315298, NCT04321993, NCT04341870, NCT04324073, NCT04327388, NCT04322773, NCT04345289, NCT02735707, NCT04357808, NCT04357860, NCT04359901
Staidson/ Pivotal
BDB-100, monocloncal anti-C5a antibody
clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Swedish Orphan Biovitrum
Gamifant (emapalumab), anti-interferon gamma antibody
clinical
Phase II/III recruiting April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04324021
Tang-Du Hospital
meplazumab, anti-CD147 antibody
clinical
Phase II/III recruiting April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04275245
Tychan/ SingHealth Investigational Medicine Unit
TY027, monoclonal antibody targeting SARS-CoV-2
clinical
Phase I started June 2020; efficacy data expected 3Q 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
University of Hong Kong (BMS)
Opdivo (nivolumab), PD-1 blocking antibody
clinical
Phase II study not yet recruiting
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04356508 NCT04333914
Wuhan Jinyintan Hospital
AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody
clinical
No trial updates since February 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Treatment of certain cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
ChiCTR2000029806
Abcore
Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ablexis / AlivaMab Discovery Services / Berkeley Lights Collaborate
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Alliance - Proteona/ NMI/ NUS Enterprise/10X Genomics; NovogeneAIT/ Twist Bioscience/ University Hospitals
Antibody for immunocompromised patients
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Amgen / Adaptive Biotechnologies
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
AstraZeneca / US Army Medical Research Institute of Infectious Diseases (USAMRIID) / University of Maryland School of Medicine
Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display
pre-clinical
Phase I trials begin in summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Atreca / BeiGene / IGM Biosciences
Novel IgM and IgA antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
CSL Behring / SAb Biotherapeutics
SAB-185, Polyclonal hyperimmune globulin (H-IG)
pre-clinical
Phase I starts early summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
CSL Behring Australia
COVID-19 Immunoglobulin, plasma derived
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Celltrion
Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Celltrion
CT-P59; Antibodies from recovered COVID-19 patients
pre-clinical
Start Phase I in July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
The Korea Health Industry Development Institute
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Centivax (Distributed Bio)
Antibody
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Chelsea and Westminster Hospital, Imperial College London
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)
Polyclonal hyperimmune globulin (H-IG), unbranded
pre-clinical
Phase I trials start in summer 2020; To patients between December 2020 and December 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Edesa Biotech / Light Chain Bioscience (NovImmune)
Monocloncal antibodies, TLR4 antagonist
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Edesa Biotech / Light Chain Bioscience (NovImmune)
Monocloncal antibodies, CXC10 antagonist
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Emergent BioSolutions
Horse plasma product (COVID-EIG)
pre-clinical
Phase II trials begin ~August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Emergent BioSolutions / National Institute of Allergy and Infectious Diseases (NIAID)
Polyclonal hyperimmune globulin (H-IG)
pre-clinical
Phase II trials begin ~August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
FairJourney Biologics / Iontas
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Generation Bio / Vir Biotechnology
Non-viral gene therapy to produce monoclonal antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
GigaGen
rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Grifols
Polyclonal hyperimmune globulin (H-IG)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Grifols
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Harbour BioMed / Erasmus MC / Utrecht University / Mount Sinai Health System / AbbVie
Antibody 47D11
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
IGY Life Sciences/ MMS Holdings/ Canadian Government National Microbiology Lab
IgY-110, anti-CoV-2 antibody (nasal spary application)
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
ImmunoPrecise Antibodies
Monoclonal antibody cocktail
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Innovent Biologics
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Kamada / Kedrion Biopharma
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ligand Pharmaceuticals
Antibodies (OmniChicken platform)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ligand Pharmaceuticals
Antibodies (OmniRat platform)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Medicago / Laval University's Infectious Disease Research Centre
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Canadian Institutes for Health Research (CIHR)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Prellis Biologics
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Public Health England (Stuart Dowall)
Purified ovine immunoglobulin from immunized sheep
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Sorrento Therapeutics / Mount Sinai Health System
COVI-SHIELD antibody cocktail that binds to three different epitopes
pre-clinical
Start Phase II trial Q3 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Tiziana Life Sciences
TZLS-501, an anti-interleukin-6 receptor monoclonal antibody (inhalation technology in development)
pre-clinical
Plan to initiate Phase 1 in Q1 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Tsinghua University / Third People's Hospital of Shenzhen / Brii Biosciences
Antibodies from recovered COVID-19 patients
pre-clinical
Phase I trial begins Q3 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
University of Texas at Austin / US National Institutes of Health / Ghent University
Linked nanobody antibody
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Vanderbilt Vaccine Center / AstraZeneca / IDBiologics
Combo of two antibodies
pre-clinical
Phase I trial begins in August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Defense Advanced Research Projects Agency/ Dolly Parton/ Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Vir Biotechnology / GSK / Samsung / WuXi Biologics / Biogen
VIR-7831 and VIR-7832, antibodies from recovered SARS patients
pre-clinical
Start Phase II ~July-September 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Virna Therapeutics/ University of Toronto
Neutralizing antibodies
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Xbiotech / BioBridge Global
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Developer / Researcher
Product Description
PHASE
Next Steps
Acer Therapeutics / US National Center for Advancing Translational Sciences (NCATS)
emetine hydrochloride
clinical
Phase II/III to start in Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
To treat viral hepatitis and varicella-virus
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ansun Biopharma / Renmin Hospital of Wuhan University
DAS181, recombinant sialidase (nebulized)
clinical
Individual patient expanded access finding released in May 2020; Phase II/III started enrolling in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT03808922 NCT04354389 NCT04298060 NCT04324489
Ascletis / Chinese research sponsors
Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C
clinical
Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Hepatitis C
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04291729 NCT04345276
Ascletis / Chinese research sponsors
ASC09, HIV protease inhibitor
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of HIV/AIDS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04261907 NCT04261270
Atea Pharmaceuticals
AT-527, oral purine nucleotide prodrug
clinical
Phase II trial to start May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Hepatitis C infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04396106
Bausch Health
Virazole (ribavirin for inhalation solution)
clinical
Phase II recruiting May 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04356677
Beech Tree Labs
BTL-tml
clinical
Has been used in 36 patients anecdotally
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of herpes virus infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BioCryst Pharmaceuticals
galidesivir
clinical
Phase Ib recruiting May 2020
n/a
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of yellow fever
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT03891420
Bukwang Pharm
Levovir (clevudine)
clinical
Phase II trial not yet recruiting
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04347915
Fujifilm Toyama Chemical / Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors / Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School / Glenmark Pharmaceuticals
Favilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenza
clinical
Fuijfilm trial to continue into July 2020; Phase III trial in India started May 2020 with results expected by July/August 2020 (Glenmark)
n/a
Funder
Funder
n/a
Life Arc (FLARE trial; PIONEER trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299 NCT04310228 ChiCTR2000029548 ChiCTR2000029496 ChiCTR2000029544 ChiCTR2000030254 NCT04336904 NCT04333589 NCT04345419
Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Diseases (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes
remdesivir, nucleotide analog
clinical
EU grants conditional authorization July 3, 2020; Gilead starting Phase I of inhalant version in June 2020; Gilead starting Phase II/III trial in pediatric patients in June 2020; FDA issued an Emergency Use Authorization on May 1, 2020; Expanded access protocols
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Ebola
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04257656, NCT04252664, NCT04292730, NCT04292899, NCT04280705, EudraCT 2020-000936-23, NCT04315948, NCT04302766, NCT04323761, NCT04349410, NCT04401579
Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial
Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor
clinical
WHO discontinues lopinavir-ritonavir arm in the SOLIDARITY trial July 2020; RECOVERY trial results released June 2020 and stopped that trial arm
n/a
Funder
Funder
n/a
UK Government (University of Oxford RECOVERY trial); Life Arc (FLARE trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299 NCT04255017 ChiCTR2000029548 ChiCTR2000029539 EudraCT 2020-000936-23 NCT04307693 NCT04315948 NCT04252885 NCT04276688 NCT02735707 NCT04321993 2020-001113-21 NCT04286503 NCT04328012 NCT04346147
Multiple global research sponsors
Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)
clinical
Phase III trials recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029541 NCT04252274 NCT04303299 NCT04304053
Multiple global research sponsors
Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections
clinical
Phase IV trials recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04252885 NCT04350684 NCT04286503 NCT04260594 NCT04273763
Plan Nacional sobre el Sida
Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029468 NCT04334928
Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)/ Merck
EIDD-2801, oral ribonucleoside analog
clinical
Phase II trial started June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405739, NCT04405570, NCT04392219
Roche; REMAP-CAP global trial
Tamiflu (oseltamivir), neuraminidase inhibitor
clinical
REMAP-CAP trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299 NCT04255017 NCT04261270 NCT02735707 NCT04338698 NCT04371601
Agastiya Biotech
AB001
pre-clinical
Phase I to start in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Anivive Lifesciences
GC376, protease inhibitor
pre-clinical
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cidara Therapeutics
antiviral Fc conjugates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cocrystal Pharma
Antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISR Immune System Regulation
ISR-50
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV
Antiviral drug combinations
pre-clinical
Unknown
n/a
Funder
Funder
n/a
EU Commission (Horizon 2020 Program)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Stanford University/ US Department of Energy's Lawrence Berkeley National Laboratory
Prophylactic antiviral CRISPR in human cells (PAC-MAN)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ViralClear Pharmaceuticals
Vicromax, broad spectrum antiviral
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
Athersys / The University of Texas Health Science Center at Houston
MultiStem, bone marrow stem cells
clinical
Phase II/III trial recruiting May 2020
n/a
Funder
Funder
n/a
Medical Technology Enterprise Consortium (MTEC)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Respiratory Distress Syndrome; Stroke
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04367077
Capricor Inc.
CAP-1002, allogenic cardiosphere-derived cells
clinical
Expanded access protocol trial ongoing May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Duchenne muscular dystrophy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04338347
Celltex
Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)
clinical
FDA approves Phase II trial on June 26, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04428801
Celularity/ Lung Biotechnology PBC
CYNK-001, allogeneic, natural killer cell therapy
clinical
Phase I/II study not yet recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various hematologic cancers and solid tumors
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04365101
Hope Biosciences
Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)
clinical
Phase II started in April 2020
n/a
Funder
Funder
n/a
Hope Biosciences Stem Cell Research Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04348435 NCT04349631 NCT04362189
Lattice Biologics
AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid
clinical
Phase I enrolling April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mesoblast/ Cardiothoracic Surgical Trials Network
Ryoncil (remestemcel-L), allogenic mesenchymal stem cells
clinical
Individual patient expanded access; Expanded access protocols; Individual patient expanded access data shared April 2020; Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04366830 NCT04371393
Naturecell
Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)
clinical
Phase I/IIa trial approved by South Korea Ministry of Food and Drug Safety in March 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Numerous trials with global research sponsors
Mesenchymal stem cells
clinical
Phase I trials ongoing May 2020; Phase I/II trials recruiting May 2020; Phase II/III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
30 trials listed in clinicaltrials.gov ChiCTR2000029990 NCT04315987 NCT04302519 NCT04288102 NCT04313322 NCT04273646 NCT04371601 NCT04315987 NCT04252118 NCT04336254 NCT04339660 NCT04371601 NCT04366063
Pluristem Therapeutics/BIH Center for Regenerative Therapy / Berlin Center for Advanced Therapies
PLX cell product, placenta-based cell therapy
clinical
Results from individual patient expanded access released in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AgeX Therapeutics/ ImStem Biotechnology
IMS001, human embryonic stem cell-derived mesenchymal stem cells (hES-MSC)
pre-clinical
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AlloVir / Baylor College of Medicine
Allogeneic T-cell therapies
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Duke-NUS Medical School
Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GC LabCell / KLEO Pharmaceuticals
Natural killer cell-based therapy
pre-clinical
Begin Phase I by end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio / NantKwest
haNK, natural killer cells
pre-clinical
Pre-IND submitted to FDA in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio / NantKwest / Be The Match BioTherapies
Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)
pre-clinical
Phase Ib trial to start June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SMSbiotech
Small mobile stem (SMS) cells
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
ALung Technologies
Hemolung Respiratory Assist System
clinical
FDA issued an Emergency Use Authorization on April 24, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Abiomed
Impella RP heart pump
clinical
FDA issued an Emergency Use Authorization on May 29, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baxter
Oxiris Blood Purification Filter
clinical
FDA issued an Emergency Use Authorization on April 23, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bellerophon
INOpulse
clinical
Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CytoSorbents Corporation
CytoSorb (blood purification device, extracorporeal cytokine adsorber))
clinical
Individual patient expanded access; FDA issued an Emergency Use Authorization on April 10, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04324528 ChiCTR2000030475 NCT04344080 DRKS00021447 NCT04385771
ExThera Medical
Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction
clinical
DOD to fund a multi-center trial June 2020; FDA issued an Emergency Use Authorization on April 17, 2020
n/a
Funder
Funder
n/a
US Department of Defense (DOD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fresenius Medical
MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)
clinical
FDA issued an Emergency Use Authorization on April 30, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Terumo BCT Inc / Marker Therapeutics AG
Extracorporeal blood purification (EBP) devices
clinical
FDA issued an Emergency Use Authorization on April 9, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
Mateon Therapeutics
OT-101, a TGF-Beta antisense drug candidate
clinical
Phase II study IND submitted to FDA on April 27, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AIM ImmunoTech / National Institute of Infectious Diseases in Japan
Ampligen; (rintatolimod)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Neurimmune / Ethris
Inhaled mRNA
pre-clinical
Phase I to start Q4 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sarepta Therapeutics / US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Antisense oligonucleotides, peptide conjugated
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sirnaomics
RNAi - testing 150 RNAis
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotech / Alnylam Pharmaceuticals
VIR-2703 (ALN-COV) siRNA candidate
pre-clinical
Phase I to start by the end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
Anixa Biosciences / OntoChem
Screening for antiviral drug candidates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
COVID-19 Therapeutics Accelerator
Scanning compound libraries
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Gates Foundation / Wellcome / Mastercard Impact Fund
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Enanta Pharmaceuticals
Screening new drugs + library of antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Exscalate4Cov, public-private consortium
Screening a chemical library of 500 billion molecules
pre-clinical
Unknown
n/a
Funder
Funder
n/a
European Commision's Horizon 2020
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Healx
Artificial intellegence-based screening to identify repurposed drug combinations
pre-clinical
Combinations will be ready for pre-clinical testing in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Janssen Pharmaceutical Companies
Scanning library of antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Materia Medica / Cyclica
Repurposing antiviral drug candidates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Merck
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Novartis
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Nuritas
AI-based screening to identify a peptide cocktail
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Partnership for Advanced Computing in Europe (PACE)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Pfizer
Scanning antiviral compounds previously in development
pre-clinical
Lead candidate (protease inhibitor) to start Phase I trial in Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quantitative Biosciences Institute Coronavirus Research Group
Reviewing existing drugs and compounds through mapping viral-human protein interactions
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Queens University Belfast
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA
Identifying drugs to repurpose
pre-clinical
Identified 30 known drugs that inhibit SARS-CoV-2 replication
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Shionogi / Hokkaido University Research Center for Zoonosis Control
Identify novel drugs
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Southwest Research Institute/ US Department of Defense (DOD)
Screening drug compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
The Henry M. Jackson Foundation for the Advancement of Military Medicine
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Southwest Research Institute
Screening drug compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Takeda
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies
Identifying drugs to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vanda Pharmaceuticals / University of Illinois at Chicago
Screening of drug compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotechnology / GSK
Identify anti-coronavirus compounds that target cellular host genes
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Wyss Institute
Identify FDA-approved drugs to repurpose to prevent or treat COVID-19
pre-clinical
Unknown
n/a
Funder
Funder
n/a
US Defense Advanced Research Projects Agency (DARPA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
4D Pharma
MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human
clinical
Phase II enrolling July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04363372, EudraCT 2020-001597-30
ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University
ARMS-1
clinical
Trial starts April 2020
n/a
Funder
Funder
n/a
Cleveland Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Influenza prophylaxis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Aarhus University
senicapoc
clinical
Phase II trial ongoing July 2020
n/a
Funder
Funder
n/a
The Danish Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sickle cell anemia; Alzheimer's disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001420-34
Abivax
ABX464
clinical
Phase IIb/III trial started July 2020, top line results expected in 2020
n/a
Funder
Funder
n/a
Bpifrance
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04393038
Aldeyra Therapeutics
ADX-629, orally available reactive aldehyde species (RASP) inhibitor
clinical
IND submission to FDA in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Systemic immune-mediated diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Aldeyra Therapeutics
ADX-1612, HSP 90 inhibitor
clinical
IND submission to FDA in Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Amarin Corp
Vascepa (icosapent ethyl), a form of eicosapentaenoic acid
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412018
Amgen
Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Apeptico
solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)
clinical
Unknown
n/a
Funder
Funder
n/a
EU Commission (Horizon 2020 Program)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Applied Biology/ Brown University/ Corpometria Institute
dutasteride, anti-androgen
clinical
Unknown
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04446429
Applied Therapeutics / numerous New York City hospitals
AT-001, aldose reductase inhibitor
clinical
Phase II recruiting July 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Diabetic cardiomyopathy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04365699
Arch Biopartners
Metablok (LSALT peptide), selective dipeptidase-1 antagonist
clinical
FDA and Health Canada approved Phase II trial start in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Lung and Kidney Inflammation
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04402957
AstraZeneca/ Saint Luke's Mid America Heart Institute; Cambridge University Hospitals NHS Foundation Trust
Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor
clinical
Phase III study started in April 2020 (AstraZeneca)
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Heart failure; Chronic kidney disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04350593, NCT04393246
AstraZeneca; ACCORD study
Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor
clinical
Case series results released June 2020; ACCORD Phase II trial to start May 2020
n/a
Funder
Funder
n/a
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346199 NCT04380688
BerGenBio; ACCORD study
bemcentinib, selective AXL kinase inhibitor
clinical
ACCORD trial started June 2020, top line data expected summer 2020
n/a
Funder
Funder
n/a
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech); University College London
Activase (alteplase), tissue plasminogen activator (tPA)
clinical
Phase II trial recruiting; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04357730, NCT04356833
BioAegis Therapeutics Inc.
recombinant human plasma gelsolin (rhu-pGSN)
clinical
Phase II trial not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Community-acquired pneumonia
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04358406
Biohaven/ Thomas Jefferson University
vazegepant, CGRP receptor antagonist
clinical
Phase II/III recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute migraine
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346615
Biomarck Pharmaceuticals
BIO-11006, inhaled peptide
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Blade Therapeutics
BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334460
CTI Biopharma
pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR
clinical
Phase III trial recruiting July 2020, results expected by the end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Myelofibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04404361
CalciMedica
Auxora (CM4620-IE), calcium release-activated calcium (CRAC) channel inhibtor
clinical
Open label phase II trial top line data released July 2020; Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pancreatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04345614
Can-Fite BioPharma
piclidenoson, A3 adenosine receptor agonist
clinical
IND (investigational new drug application) expected to be filed with FDA by end of June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis; psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04333472
Chimerix
DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin
clinical
Phase II/III trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute myeloid leukemia
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389840
Cyclacel Pharmaceuticals / University of Edinburgh
fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cyclacel Pharmaceuticals / University of Edinburgh
roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Dompe farmaceutici (as part of Exscalate4CoV)
raloxifene (Evista), an estrogen agonist/antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center
Ryanodex (dantrolene sodium), skeletal muscle relaxant
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Eiger BioPharmaceuticals, Inc.
Peginterferon lambda
clinical
Phase II began in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Hepatitis Delta
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04331899
Eisai
Eritoran, TLR-4 antagonist
clinical
Added to REMAP-COVID trial in June 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sepsis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital/ TACTIC-E trial (Cambridge University Hospitals NHS Foundation Trust)
EDP1815, oral single strain of microbe
clinical
Part of Phase II/III Phase TACTIC-E trial and interim data expected 4Q 2020; Phase II US trial to start July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Psoriasis and Atopic Dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04393246
Exvastat Ltd / Global sponsors
Gleevac (imatinib), kinase inhibitor
clinical
Phase II and Phase III trials recruiting July 2020
n/a
Funder
Funder
n/a
Innovative Medicines Initiative
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346147, NCT04357613, NCT04356495, NCT04422678, NCT04394416
FSD Pharma
FSD-201 (ultramicronized palmitoylethanolamide)
clinical
Phase I topline results released June 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Respiratory infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Faron Pharmaceuticals / REMAP-CAP global trial / WHO SOLIDARITY trial/ various global researchers
Traumakine (interferon beta 1-a)
clinical
Results from various trials released June 2020; REMAP-CAP trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT02735707, IRCT20100228003449N28, NCT04350671, NCT04343768, NCT04315948
Feinstein Institutes for Medical Research at Northwell Health/ Alchem
Pepcid (famotidine), histamine-2 (H2) receptor antagonist
clinical
Phase II study underway in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389567, NCT04370262
Fulcrum Therapeutics
losmapimod, oral selective p38 mitogen activated protein kinase inhibitor
clinical
Phase III trial to begin June 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Multiple indications, including facioscapulohumeral muscular dystrophy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Genentech
MSTT1041A (anti-ST2, the receptor for IL-33)
clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Genentech
UTTR1147A (IL-22-Fc)
clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Genetic Engineering and Biotechnology Center (CIGB), Cuba
CIGB-258, immunoregulatory peptide
clinical
Unknown
n/a
Funder
Funder
n/a
Ministry of Public Health of Cuba
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
https://rpcec.sld.cu/ensayos/RPCEC00000313-Sp
Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon)
Novaferon, Nova, interferon, licensed in China for Hepatitis B
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029573 ChiCTR2000029496
Immunic, Inc.
IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor
clinical
Phase II trial started June 2020, top line results expected in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Ulcerative colitis; remitting multiple sclerosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio / NantKwest
N-803, IL-15 "superagonist" (Nogapendekin alfa inbakicept)
clinical
Phase Ib trial to start June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bladder Carcinoma In Situ
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04385849
Innovation Pharmaceuticals
Brilacidin, a defensin mimetic
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Insmed Inc.
brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)
clinical
Phase II study to begin enrollment in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bronchiectasis and other inflammatory diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001643-13
Institut National de la Sante et de la Recherche Medicale (Merck KGaA)
Rebif (interferon beta-1a)
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-000936-23 NCT04315948
KD Pharma / SLA Pharma
EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Familial adenomatous polyposis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Karyopharm Therapeutics
Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound
clinical
Phase II trial ongoing July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04355676, NCT04349098
King's College London
Flarin (lipid ibuprofen)
clinical
Phase IV trial recruiting in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334629
Laurent Pharmaceuticals
LAU-7b (fenretinide)
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat exaggerated inflammatory response in adult cystic fibrosis patients
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04417257
Massachusetts General Hospital; University of British Columbia; Sanotize Research and Development; Bellerophon Pulse Technologies
Nitric oxide
clinical
Mass. General Hopsital Phase II trial ongoing July 2020; other Phase II trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04305457, NCT04312243, NCT04306393, NCT03331445, NCT04443868, NCT04337918, NCT04456088, NCT04421508, NCT04383002, NCT04388683, NCT04338828
MediciNova/ Yale
MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor
clinical
Phase II trial FDA approved and not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of numerous neurodegenerative diseases and substance dependence
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04429555
MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University; other global research sponsors
ivermectin
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04343092, NCT04345419, NCT04351347, NCT04407507, NCT04392713, NCT04425707, NCT04438850, NCT04405843, NCT04429711, NCT04374279, NCT04360356, NCT04381884
Multiple global research sponsors
Cozaar (losartan), angiotensin II receptor blocker (ARB)
clinical
Phase II, Phase II/III, and Phase IV trials recruiting in May 2020
n/a
Funder
Funder
n/a
COVID-19 Treatment Accelerator
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04312009 NCT04311177 NCT04349410 NCT04335123 NCT04343001 NCT04328012 NCT04340557
Multiple global research sponsors
heparin; low molecular weight heparin (enoxaparin), anticoagulant
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04366960, NCT04360824, NCT04359277, NCT04354155, NCT04367831, NCT04345848, NCT04373707, NCT04372589, NCT04362085, NCT04344756, NCT04408235, NCT04406389, NCT04400799, NCT04377997, NCT04393805, NCT04427098
Multiple global research sponsors
Diovan (valsartan), angiotensin II receptor blocker (ARB)
clinical
Phase IV trials recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04335786 NCT04330300
Multiple global research sponsors, including UK SPIKE-1 trial
camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis
clinical
Phase I/II, Phase II, and Phase III trials recruiting in May 2020
n/a
Funder
Funder
n/a
LIfeArc (SPIKE-1 trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04321096 NCT04353284 NCT04338906 NCT04374019 NCT04355052
Multiple global research sponsors, including University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea/ Daiichi Sankyo (inhalation formulation)
nafamostat, approved in Japan to treat pancreatitis and other diseases
clinical
University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04352400, NCT04418128
National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly)
Olumiant (baricitinib), Janus kinase (JAK) inhibitor
clinical
Eli Lilly Phase III trial started June 2020; NIAID trial remdesivir + baricitinib recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04321993, NCT04320277, NCT04340232, NCT04280705, NCT04345289, NCT04346147, NCT04358614, NCT04373044, NCT04438629, NCT04421027, NCT04362943, NCT04393051, NCT04401579, NCT04390464, NCT04399798, NCT04365764
NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health/ Houston Methodist Hospital
Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide (RLF-100)
clinical
FDA grants Fast Track Designation June 2020; Phase II/III trial started in April 2020; Expanded access protocols
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04311697, NCT04453839, NCT04360096
Novartis / Incyte, numerous researchers globally
Jakafi/jakavi (ruxolitinib)
clinical
Novartis/Incyte Phase III trial started April 2020; Expanded access protocols
n/a
Funder
Funder
n/a
LIfeArc (RAVEN trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029580, NCT04334044, NCT04331665, NCT04337359, NCT04348071, NCT04338958, NCT04348695, NCT04355793, NCT04354714, NCT04377620, NCT04362137, NCT04366232, NCT04361903, NCT04374149, NCT04338958, NCT04359290, NCT04414098
Noveome Biotherapeutics/ Singota Solutions
ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells
clinical
Phase I/II to start in Q4 2020
n/a
Funder
Funder
n/a
Commonwealth of Pennsylvania
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Multiple ophthalmic indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Noxopharm
Veyonda (idronoxil)
clinical
Phase I to begin in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Prostate cancer
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Numerous research sponsors globally
colchicine
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326790 NCT04328480 NCT04322565 NCT04322682
Numerous research sponsors globally
dipyridamole (Persantine), anticoagulant
clinical
Phase II recruiting July 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04424901, NCT04391179, NCT04410328
Numerous trials with global research sponsors including World Health Organization SOLIDARITY trial; ORCHID trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial
Chloroquine/ Hydroxychloroquine, antimalarial
clinical
Prevention studies continue in Asia; NIH study stopped in June 2020; Novartis discontinues trial due to feasibility of recruitment in June 2020; WHO discontinues hydroxychloquine arm in the SOLIDARITY trial July 2020; FDA revoked the March 28, 2020 Emergency Use Authorization on June 15, 2020; RECOVERY trial prelim results released June 2020, trial arm stopped; Univ. of Minnesota trial results released June 2020
n/a
Funder
Funder
n/a
COVID-19 Treatment Accelerator (University of Washington/NYU trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial); Life Arc (PIONEER trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517, NCT04303507, NCT04303299, NCT04304053, NCT04307693, NCT04316377, NCT04315948, NCT04321993, ECT2020-001113-21, NCT04323527, NCT04333732, NCT04332991, NCT04345419, NCT04341870, NCT04345289, NCT02735707, NCT04351347, NCT04341493, NCT04332094, NCT04349410, NCT04286503, NCT04328012, NCT04346147
Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.
Methylprednisolone/ ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids
clinical
RECOVERY trial results released (dexamethasone) June 2020
n/a
Funder
Funder
n/a
UK Government (University of Oxford RECOVERY trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04244591, NCT04263402, NCT04273321, ChiCTR2000029656, ChiCTR2000029386, NCT02735707, NCT04330586, 2020-001113-21, NCT04345445, NCT04349410, NCT04329650
OncoImmune
CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)
clinical
Phase III trial progress report released in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Graft versus Host Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04317040
Orpheris (Ashvattha Therapeutics)
OP-101, dendrimer-based therapy
clinical
FDA agreed to Phase II June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
PTC Therapeutics
PTC299, oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH)
clinical
Phase 2/3 trial to start in June 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Panoptes Pharma GmbH
PP-001
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Severe eye diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Partner Therapeutics/ Singapore General Hospital/ University Hospital, Ghent
Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )
clinical
Phase II and Phase IV trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326920, NCT04400929
Pfizer; other global research sponsors
Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor
clinical
Pfizer and other Phase II trial not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04332042, NCT04415151, NCT04390061, NCT04412252
PharmaMar/ Boryung Pharmaceutical/ Hospitals in Spain
Aplidin (plitidepsin), approved in Australia to treat multiple myeloma
clinical
Phase I trial recruiting July 2020; Trials in Korea to start 3Q 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04382066
Pharming
Ruconest (recombinant human C1 esterase inhibitor)
clinical
Phase II trial not yet recruiting July 2020; compassionate use
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04414631
PhaseBio
PB1046, long-acting, sustained release human vasoactive intestinal peptide (VIP) analogue
clinical
Phase 2 trial expected to start dosing end of June 2020 and results in Q4 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary arterial hypertension
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04433546
Pulmotect
PUL-042 inhalation solution
clinical
Phase II trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Prevent and treat respiratory complications in immunosuppressed cancer patients
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04312997, NCT04313023
RedHill Biopharma
Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor
clinical
Preliminary data from individual patient expanded access released in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RedHill Biopharma/ NIAID
RHB-107 (upamostat, WX-671), serine protease inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Resverlogix
apabetalone (RVX-208), selective BET (bromodomain and extra-terminal) inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat various conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Romark Laboratories; various researchers globally
nitazoxanide, antiprotozoal
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04351347 NCT04348409 NCT04343248 NCT04341493 NCT04345419
SciTech Development, LLC
ST-001 nanoFenretinide (fenretinide)
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
non-Hodgkin's lymphoma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Shanghai Jiao Tong University School of Medicine
Recombinant human interferon alpha-1b
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04320238
Sun Pharmaceutical Industries Ltd
AQCH, plant-derived (phytopharmaeutical) drug
clinical
Phase II trial started June 2020, results expected by October
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Swedish Orphan Biovitrum / REMAP-CAP global trial
Kineret (anakinra), interleukin-1 receptor antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04324021, NCT02735707, NCT04339712, NCT04330638, NCT04366232, NCT04443881
Synairgen / University of Southampton
SNG001, inhaled formulation of interferon beta-1a
clinical
Phase II began in March 2020; Initial results expected by end of June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma patients with cold or flu infection; COPD patients with viral infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04385095
The First Affiliated Hospital of Fujian Medical University/Novartis
Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator
clinical
Phase II trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04280588
Union Therapeutics/ Institute Pasteur Korea/ Daewoong Therapeutics; First Wave Bio
UNI9011 (Union Therapeutics), FW-1022 (First Wave Bio), DWRX2003 (Daewoong) niclosamide
clinical
Danish Medicines Agency approved a Phase I trial July 2020 (UN9011, Union Therapeutics); Daewoong to apply for Phase I trial in Korea in July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Atopic Dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04345419, NCT04399356, NCT04436458
University of Alabama at Birmingham
Lysteda/Cyklokapron (tranexamic acid), an antifibrinolytic
clinical
Phase II not yet recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04338074 NCT04338126
University of British Columbia/Apeiron Biologics
APN01; recombinant soluble human Angiotensin Converting Enzyme 2
clinical
Phase II began in April 2020
n/a
Funder
Funder
n/a
Austrian Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Hawaii (Boehringer Ingelheim)
Micardis (telmisartan)
clinical
Phase II not yet recruiting as of April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04360551
Vanda Pharmaceuticals / Feinstein Institutes for Medical Research at Northwell Health
tradipitant, a neurokinin-1 receptor antagonist
clinical
Phase III trial started in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Gastroparesis, motion sickness, and atopic dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326426
Various researchers globally, including University of Oxford
almitrine
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc (University of Oxford trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various lung diseases including Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04357457, NCT04380727
Various researchers worldwide, including Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd.
leflunomide, pyrimidine synthesis inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Life Arc (Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd. trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04361214
Various researchers worldwide, including University College London/ The Francis Crick Institute (COVASE study)
Pulmozyme (nebulised dornase alfa), a recombinant DNase enzyme
clinical
Phase III trials recruiting June 2020
n/a
Funder
Funder
n/a
Life Arc (COVASE study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04409925, NCT04359654, NCT04387786, NCT04355364, NCT04402944, NCT04402970
Vicore Pharma
VP01, Angiotensin II Type 2 receptor activator
clinical
Unknown
n/a
Funder
Funder
n/a
Life Arc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary fibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ViralClear Pharmaceuticals
merimepodib, IMPDH inhibitor
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Chronic Hepatitis C; Psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04410354
Washington University School of Medicine in St. Louis
Luvox (fluvoxamine), a selective serotonin reuptake inhibitor
clinical
Phase II trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04342663
Zydus Cadila Group; The Camelot Foundation
interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep
clinical
Phase II/III enrolling May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04273763 NCT04349410
Zydus Cadila/ Avant Sante Research Center
desidustat, a hypoxia inducible factor prolyl hydroxylase inhibitor
clinical
Phase IIb trials approved to start in Mexico July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Chronic Kidney Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
aTyr
ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2
clinical
Phase II study started in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary sarcoidosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412668
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
A successful vaccine would be able to protect the population from COVID-19. Developers from around the world are using different platforms, from tested ways to induce immunity in a vaccinated person (e.g., live attenuated virus vaccines), to innovative platforms never used before (e.g., DNA-based vaccines), to build vaccines to protect people against COVID-19 disease. Each type offers unique benefits and challenges and we will likely need more than one approved vaccine to vaccinate every person around the globe.
Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices
DNA plasmid vaccine with electroporation; INO-4800
stage-1
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I initial data released June 30, 2020; Phase II/III trials start July/August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04336410, NCT04447781
Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex
DNA vaccine (GX-19)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445389
Ege University
DNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University/ AnGes/ Takara Bio/ Cytiva
DNA plasmid
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
JapicCTI-205328
Scancell/ University of Nottingham/ Nottingham Trent University
DNA plasmid vaccine RBD&N
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mediphage Bioceuticals/ University of Waterloo
msDNA vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Zydus Cadila Healthcare Limited
DNA plasmid
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II to start in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026352
Entos Pharmaceuticals/ Cytiva
DNA; Covigenix
pre-clinical
Funder
Funder
n/a
Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II to start in late July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
DNA plasmid vaccine S, S1, S2, RBD & N
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chula Vaccine Research Center
DNA with electroporation
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Takis/ Applied DNA Sciences/ Evvivax
DNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal results released in May 2020; Phase I to start in fall 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Symvivo
bacTRL-Spike
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Immunomic Therapeutics / EpiVax / PharmaJet
DNA plasmid, needle-free delivery
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BioNet Asia
DNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OPENCORONA - Cobra Biologics / Karolinska Institute
DNA with electroporation
pre-clinical
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Sinovac/ Instituto Butantan
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)
stage-2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III enrolling in Brazil in July 2020; Phase II started in June 2020; preliminary results from Phase I/II trials released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04456595, NCT04352608, NCT04383574
Institute of Medical Biology, Chinese Academy of Medical Sciences
Inactivated
stage-2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412538
Wuhan Institute of Biological Products/ Sinopharm
Inactivated
stage-2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Early Phase I/II trial results released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000031809
Beijing Institute of Biological Products/ Sinopharm
Inactivated
stage-2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
In Phase II, June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000032459
Selcuk University
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
KM Biologics
Inactivated (inactivated + alum)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for JE, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valneva/ Dynavax
Inactivated (Inactivated + CpG 1018), VLA2001
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Japanese Encephalitis
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Inactivated whole virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sinovac/ Dynavax
Inactivated (inactivated + CpG 1018)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / NIBIOHN
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Beijing Minhai Biotechnology Co., Ltd.
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.
Codon deoptimized live attenuated vaccines
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Meissa Vaccines 
MV-014-210
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase 1 beginning of 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Indian Immunologicals Ltd/ Griffith University
Codon deoptimized live attenuated virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Codagenix / Serum Institute of India
Codon deoptimized live attenuated virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal data in summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca
Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)
stage-3
Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance
Related use
Related use
n/a
Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III enrolling in Brazil end of June 2020; South African trial starts end of June 2020; Will join US Operation Warp Speed Phase III vaccine trials in August 2020; Phase II/III trials enrolling May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISRCTN89951424, NCT04324606, EudraCT 2020-001072-15, EudraCT 2020-001228-32, NCT04400838, ISRCTN89951424, PACTR202006922165132
CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)
stage-2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Approved for military use in China on June 25, 2020; Phase II started April 2020; initial results released May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04313127 ChiCTR2000030906 ChiCTR2000031781 NCT04398147
Gamaleya Research Institute
Adeno-based
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04437875
Ankara University
Adenovirus-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ID Pharma
Sendai virus vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
DZIF - German Center for Infection Research/ IDT Biologika GmbH
Non-replicating viral vector; MVA-S encoded
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for many pathogens
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent
Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)
pre-clinical
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, HIV, RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine trials in September 2020; Start Phase I/IIa July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Influenza A H1N1 vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio/ NantKwest
Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I in June 2020; vaccine to be included in US Operation Warp Speed trials according to company
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valo Therapeutics Ltd
Adenovirus-based + HLA-matched peptides (Pan-Corona)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Manitoba
Non-replicating viral vector; dendritic cell-based vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Georgia/ University of Iowa
Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Stabilitech Biopharma Ltd
Oral Ad5 S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
MVA-S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeoVax / BravoVax
Non-replicating viral vector; MVA encoded VLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for LASV, EBOV, MARV, HIV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greffex
Non-replicating viral vector; Ad5 S (GREVAX™ platform)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
Non-replicating viral vector, MVA expressing structural proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bharat Biotech/ Thomas Jefferson University
Recombinant deactivated rabies virus containing S1
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vaxart / Emergent BioSolutions
Non-replicating viral vector; Oral Vaccine platform
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial to begin in the second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ReiThera/ Leukocare/ Univercells
Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I in summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/ Viralgen/ Aldevron/ Catalent/ Penn Medicine
AAVCOVID, Adeno-associated viral vector (AAV), spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase 1 to begin second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Altimmune / University of Alabama at Birmingham
AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial to begin Q3 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma
Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial started July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04453852
Clover Biopharmaceuticals Inc./ GSK/ Dynavax
Protein subunit, native like trimeric subunit spike protein
stage-1
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, RSV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial started June 2020, preliminary results expected August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405908
Novavax/ Emergent BioSolutions/ Praha Vaccines/Serum Institute of India/ AGC Biologics
Protein subunit; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (NVX-CoV2373)
stage-1
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense
Related use
Related use
n/a
Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine trials, Phase III trial to start in fall 2020; Phase I/II started May 2020; top-line data expected July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04368988
InnoMedica
Protein subunit, TaliCoVax19
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bogazici University
Peptide + novel adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Izmir Biomedicine and Genome Center
Recombinant S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Virginia
S subunit intranasal liposomal formulation with GLA/3M052 adjs.
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunoPrecise/ LiteVax BV
Spike-based (epitope screening)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences
Adjuvanted recombinant protein (RBD-Dimer)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Received approval to launch clinical trials in China in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445194
National Research Centre, Egypt
Protein Subunit S, N, M & S1 protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria
Subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baiya Phytopharm/ Chula Vaccine Research Center
Plant-based subunit (RBD-Fc + Adjuvant)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada
Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I testing by summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax
Outer Membrane Vesicle (OMV)-subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of San Martin and CONICET, Argentina
Protein subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Yisheng Biopharma
Protein subunit, recombinant protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
WRAIR / USAMRIID
Protein subunit; S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Verndari/ University of California, Davis
Spike protein; VaxiPatch microneedle array dermal patch
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccines against influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vabiotech
Protein subunit, recombinant S protein in IC-BEVS
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vaxil Bio
Protein subunit; peptide
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Queensland / GSK / Dynavax/ CSL
Protein subunit; molecular clamp stabilized Spike protein
pre-clinical
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Alberta
Protein subunit; spike based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Hepatitis C
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of California, San Diego
Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch
pre-clinical
Funder
Funder
n/a
National Science Foundation (Rapid Response Research [RAPID] grant)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quadram Institute Biosciences
OMV-based vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Flu A, plaque
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MOGAM Institute for Biomedical Research, GC Pharma
Protein subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
LakePharma, Inc.
Protein subunit, nanoparticle vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Lomonosov Moscow State University
Structurally modified spherical particles of the tobacco mosaic virus (TMV)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Neovii/Tel Aviv University
RBD-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax
S-2 P protein + CpG 1018
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Institute of Infectious Disease, Japan
Protein subunit, S protein + adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan
Protein subunit, VLP-recombinant protein + adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Kentucky BioProcessing (British American Tobacco)
RBD-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OncoGen
Protein subunit, synthetic long peptide vaccine candidate for S and M proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MIGAL Galilee Research Institute
Protein subunit; oral E. coli-based protein expression system of S and N proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
PDS Biotechnology
PDS-0203; Versamune T-cell activating technology
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccines against cancers, HBV, influenza, and tuberculosis
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max-Planck Institute of Colloids and Interfaces
Targeted (Langerhans cell specific) protein subunit; spike based
pre-clinical
Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax
Outer Membrane Vesicle (OMV)-peptide
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Innovax / Xiamen University / GSK
Protein subunit; COVID-19 XWG-03 truncated Spike proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
iBio / CC-Pharming
Protein subunit; Subunit protein, plant produced
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing
Protein subunit (gp-96 backbone)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Protein subunit; subunit vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ExpreS2ion
Protein subunit, drosophila S2 insect cell expression system VLPs
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Protein subunit; peptide vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Generex / EpiVax
Protein subunit; Ii-Key peptide
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, SARS-CoV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Flow Pharma
Protein subunit, peptide
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EpiVax / University of Georgia
Protein subunit; S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Inf H7N9
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EpiVax
Protein subunit EPV-CoV-19
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AnyGo Technology
Protein subunit, recombinant S1-Fc fusion protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BiOMVis Srl/ University of Trento
OMV-based vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baylor College of Medicine
Protein subunit; S1 or RBD protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Biological E Ltd
Protein subunit; adjuvanted protein subunit (RBD)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Applied Biotechnology Institute, Inc.
Orally delivered, heat stable subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Axon Neuroscience SE
Peptides derived from Spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chulalongkorn University/ GPO, Thailand
RBD protein fused with Fc of IgG + Adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AJ Vaccines
Protein subunit; S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Pittsburgh
PittCoVacc, Protein subunit, microneedle arrays S1 subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start as early as June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Cambridge / DIOSynVax
Protein subunit; S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Influenza, Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start as early as June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sanofi Pasteur / GSK
Protein subunit; S protein, baculovirus production
pre-clinical
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II to start in September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
VIDO-InterVac, University of Saskatchewan
Protein subunit, adjuvanted microsphere peptide
pre-clinical
Funder
Funder
n/a
The Government of Saskatchewan and the Canadian Federal Government
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal testing results expected in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic
Protein subunit, capsid-like particle (CLP)
pre-clinical
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to begin by February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
UMN Pharma (Shionogi)
Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology
pre-clinical
Funder
Funder
n/a
Japan Agency for Medical Research and Development
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Zydus Cadila Healthcare Limited
Replicating viral vector; measles vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
DZIF - German Center for Infection Research/ CanVirex AG
Measles virus (S, N targets)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Zika, H7N9, CHIKV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Israel Institute for Biological Research/ Weizmann Institute of Science
VSV-S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The University of Hong Kong
Replicating viral vector, influenza vector expressing RBD
pre-clinical
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The Lancaster University, UK
Avian paramyxovirus vector (APMV)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Western Ontario
Replicating viral vector; VSV-S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Tonix Pharma / Southern Research
Replicating viral vector; horsepox vector expressing S protein; TNX-1800
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for smallpox, monkeypox
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
KU Leuven
Replicating viral vector; YF17D Vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Replicating viral vector; measles vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fundacao Oswaldo Cruz and Instituto Buntantan
Attenuated Influenza expressing an antigenic portion of the Spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Replicating viral vector; VSV vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BIOCAD / IEM
Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Wisconsin-Madison / FluGen/ Bharat Biotech
M2-deficient single replication (M2SR) influenza vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I trial in fall 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IAVI/ Merck
Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein
pre-clinical
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine trials; clinical studies to start in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Institut Pasteur / Themis / University of Pittsburgh / Merck
Replicating viral vector; measles vector
pre-clinical
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Start animal testing in April 2020; clinical testing to start later in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Moderna/ NIAID/ Lonza/ Catalent/ Rovi
RNA; LNP-encapsulated mRNA (mRNA 1273)
stage-2
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine Phase III trials in July 2020; Completed enrollment for both cohorts of the Phase II study in early July 2020; FDA granted fast track designation May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04283461, NCT04405076
BioNTech/ Fosun Pharma/ Pfizer
3 LNP-mRNAs; BNT162
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III trial may start as early as July 2020 (not participating in the NIH testing program); Phase I/II started April 2020; first data released July 1, 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001038-36, NCT04368728
CureVac
RNA; mRNA
stage-1
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB)
Related use
Related use
n/a
Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I/IIa trial June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04449276
Imperial College London/ VacEquity Global Health
RNA; LNP-nCoVsaRNA
stage-1
Funder
Funder
n/a
UK Government
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II trial started June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISRCTN17072692
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech
mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000034112
Selcuk University
mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chula Vaccine Research Center/University of Pennsylvania
LNP-mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious Disease
Self amplifying RNA, self-assembling delivery system
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Arcturus/Duke-NUS/ Catalent
LUNAR-COV19; RNA; mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I trial August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ziphius Therapeutics/ Ghent University
RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Tokyo / Daiichi-Sankyo
RNA; LNP-encapsulated mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RNAimmune, Inc.
RNA; several mRNA candidates
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max Planck Institute of Colloids and Interfaces
mRNA in targeted LPNs (Langerhans cell specific)
pre-clinical
Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeneOne Life Science / Houston Methodist
RNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greenlight Biosciences
mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding RBD
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding VLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
China CDC / Tongji University / Stermina
RNA; mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
RNA; mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
RNA; Replicating defective SARS-CoV-2 derived RNAs
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CanSino Biologics/Precision Nanosystems
RNA; mRNA lipid nanoparticle (mRNA-LNP)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sanofi Pasteur / Translate Bio
LNP-mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start Q4 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp
RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BIOCAD
RNA; liposome-encapsulated mRNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal studies begin in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Medicago Inc./ GSK
VLP (CoVLP)+ Adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medicago Inc./ Dynavax
VLP (CoVLP)+ Adjuvant (CpG 1018)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start mid-July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medicago Inc./ Université Laval
VLP; plant-derived VLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I in July/August 2020; Phase II by the end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04450004
Middle East Technical University
VLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OSIVAX
VLP (COVID-19 and SARS1)
pre-clinical
Funder
Funder
n/a
European Innovation Council (EIC)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Doherty Institute
VLP; unknown
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
VBI Vaccines / National Research Council of Canada
Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I testing by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital
VLP + Adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols
S protein integrated in HIV VLPs
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Sao Paulo
VLPs peptides/whole virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Saiba GmbH
VLP; virus-like particle, based on RBD displayed on virus-like particle
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Navarrabiomed, Oncoimmunology group
Virus-like particles, lentivirus, and baculovirus vehicles
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ARTES Biotechnology
VLP; eVLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for malaria
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Imophoron Ltd / Bristol University's Max Planck Centre
VLP; ADDomerTM multiepitope display
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Adeleke University
Unknown
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NidoVax
unknown; IMT504 technology
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vault Pharma/ University of California Los Angeles
nanoparticles (vaults) as second-line defense of infection
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vivaldi Biosciences/ Esco Aster Pte Ltd
Chimeric vaccine (coronavirus and influenza)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Universite Laval
Unknown
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotechnology / GSK
Unknown
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Tulane University
Unknown
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SmartPharm Therapeutics / Sorrento Therapeutics
Gene-encoded antibody vaccine, non-viral nanoparticle delivery
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Shenzhen Geno-Immune Medical Institute
LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04276896
Shenzhen Geno-Immune Medical Institute
Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04299724
Precision Vaccines Program at Boston Children's Hospital
Unknown